Swiss cannabis pilots point to safer consumption without higher use

Legal pharmacy access has not pushed consumption higher, according to an interim assessment of Switzerland's cannabis pilot schemes. The findings, presented in Bern on September 7, 2026, give federal lawmakers early evidence that regulated access can alter how people use cannabis without increasing how much they consume.

The assessment covers pilots in Bern, Biel and Lucerne. The scheme allows registered participants to obtain cannabis through regulated channels, including pharmacies, while researchers track consumption and health related behaviour. The project began in 2024 and has so far operated without security incidents.

The result matters because Switzerland is preparing the next revision of the Federal Act on Cannabis Products. Policymakers have been testing whether controlled access can bring consumers into contact with product information and health guidance. The early findings support that approach, while leaving wider questions about long term health effects, participation and enforcement unanswered.

The government has extended the pilot until October 2028, giving researchers more time to assess whether the initial pattern holds. For now, the evidence from the three participating cities points to a shift in consumption practices rather than an expansion of use.

Vaping is becoming more common among participants, one of the clearest behavioural changes identified in the interim assessment. Researchers say users are increasingly choosing methods considered lower risk than smoking, a change that places harm reduction at the centre of the Swiss experiment.

The distinction is important. Regulated sales can give users access to advice about preparation, dosage and possible health risks. The source assessment does not quantify the share of participants who vape, nor does it claim that vaping is risk free. It reports a direction of travel: people receiving cannabis through the pilots are increasingly selecting alternatives to smoking.

That information can travel beyond the official points of sale. Around 71% of participants said they had passed advice on to people in their social circle. The figure suggests that the pilot's effects may extend beyond registered buyers, although the available findings do not establish how accurately that advice is followed or how far it spreads.

Switzerland's approach therefore combines controlled supply with information. The next assessments will need to show whether the change in consumption method persists, whether it reduces health risks over time and how it affects people who remain outside the pilot schemes.

Three cities have supplied the first interim evidence, but Switzerland's experiment now reaches well beyond Bern, Biel and Lucerne. Cannabis trials are also underway in Zurich, Basel, Lausanne, Geneva, St Gallen and Basel Country, creating a broader basis for comparing regulated access across different local settings.

The pilots do not form a single national retail system. Each project operates within the federal framework and serves defined groups of participants. That structure allows researchers and local authorities to observe how access works in pharmacies and other approved settings while maintaining controls around eligibility, supply and monitoring.

The absence of security incidents since 2024 is another early finding. It does not resolve every concern surrounding diversion, public consumption or the effect of cannabis on vulnerable users. Those issues require continued monitoring, particularly as more municipalities gain experience with the model.

Regional evidence will be especially relevant to the federal law revision. Results from larger cities may differ from those in smaller urban areas or cantonal settings. Comparing participation, consumption patterns and reported harms can help lawmakers decide which safeguards belong in a future national framework and which should remain locally administered.

October 2028 is now the key deadline for Switzerland's cannabis evidence base. The federal government's extension gives the pilots additional time to measure whether regulated access continues to avoid higher consumption while encouraging lower risk practices.

The findings will feed into the revision of the Federal Act on Cannabis Products. Lawmakers will have to weigh the early results against evidence that remains incomplete. The current assessment reports no increase in consumption, more use of vaping and no security incidents in the participating pilots. It does not provide a national estimate of cannabis use, a long term health assessment or a full comparison between participants and nonparticipants.

That distinction will shape the political debate. Supporters of regulated access can point to a controlled system that connects consumers with advice and has not produced the rise in consumption some critics feared. Opponents will continue to scrutinise product strength, access for young people, impaired driving and the possibility of cannabis moving beyond authorised channels.

Switzerland's next step will depend on the accumulated evidence from all participating regions. The interim assessment has established a clear direction for the pilots. The remaining task is to determine whether that direction is strong enough to guide federal law.